BRAF and neoplasm: In an NF–1 genetically engineered mouse model of plexiform neurofibroma lacking BRAF alterations, tovorafenib showed no antitumor activity; moreover, although not statistically significant, tumor volume increased in 2 out of 12 mice (approximately 17%) [26].